Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 17/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22503037 | 0.86 | MAP4K1 (0.34) | MAP4K1PIK3CD | |
| SCHEMBL21652611 | 0.81 | MAP4K1 (0.46) | MAP4K1 | |
| SCHEMBL23107316 | 0.80 | MAP4K1 (0.40) | MAP4K1GAASMN1; SMN2BRD4BRD2 | |
| SCHEMBL22885099 | 0.78 | MAP4K1 (0.41) | MAP4K1GAASMN1; SMN2BRD4BRD2 | |
| SCHEMBL20517013 | 0.78 | MAP4K1 (0.39) | MAP4K1PIK3CDGAASMN1; SMN2BRD4 | |
| SCHEMBL21334689 | 0.77 | MAP4K1 (0.37) | MAP4K1PIK3CDGAASMN1; SMN2 | |
| SCHEMBL23790734 | 0.76 | MAP4K1 (0.33) | MAP4K1 | |
| SCHEMBL13455921 | 0.72 | — | — | |
| SCHEMBL23429316 | 0.70 | MAP4K1 (0.40) | MAP4K1 | |
| SCHEMBL23790716 | 0.70 | PDPK1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | MAP4K1 59/4885PIK3CD 2683/4885GAA 1019/4885 |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | MAP4K1 99/4885PIK3CD 2012/4885GAA 905/4885 |
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | MAP4K1 67/4885PIK3CD 1553/4885GAA 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.